Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Gumpoldsberger, M.
Outcome of breast cancer patients treated with neoadjuvant therapy considering the Residual Cancer Burden
Humanmedizin; [ Diplomarbeit ] Graz Medical University; 2017. pp. 51
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Balic Marija
- Müller Hannah Deborah
- Altmetrics:
- Abstract:
- As breast cancer causes most tumor related deaths in Austrian women, the evaluation of risk and prognosis remains a challenge for physicians. Therefore, the RCB-score was introduced to measure response to neoadjuvant treatment and enable physicians to make more accurate prognoses on long-term survival. It was the goal of our research to independently test the prognostic value of the RCB-score on disease-free survival (DFS) and overall survival (OS). A retrospective analysis was performed on 212 breast cancer patients who received neoadjuvant therapy and surgery at the Medical University of Graz. We included patients with neoadjuvant chemotherapy, endocrine therapy and HER2-directed therapy. The RCB-score and group (0, I, II, III) were calculated according to Symmans et al. Information about age, histological subtypes, receptor density, received regimen and follow-up was collected from paper-based files. Microsoft Excel® and IBM SPSS® were used for statistical examination. Kaplan-Mayer curves were used to calculate the correlation of the RCB-score with DFS and OS. We were able to confirm the general prognostic value of the RCB-score to DFS (p=0.000006) and OS (p=0.000306). Furthermore, the pathological T-status correlated with both DFS (p=0.0003) and OS (p=0.005). In contrast, menopause status, endocrine-receptor density, HER2-status and histological subtype did not correlate with the survival factors.